Skip to main content

Alzheimer’s Amyloid-Clearing Monoclonal Antibody Drug Lecanemab Shows Positive Results, Poised for FDA Approval

This shows pillsLecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.

from Neuroscience News https://ift.tt/GM6Ke0F
Labels:

Comments

Post a Comment

Popular posts from this blog

More Evidence that Patient Portals Improve Patient Care

Of all the medical specialties, neurologists see some of the most complex patients. This idea bears out anecdotally among the neurologists we have interviewed here at Neurology Insights but also statistically. In this 2018 study published in JAMA , neurologists were ranked #3 among physician types for patient complexity as well as for their number of comorbidities (Nephrologists were ranked #1, if you must know). Not surprisingly, among the comorbidities they listed: diabetes . In addition to the neurological sequelae associated with diabetes, this complex and chronic condition often requires well-coordinated care involving repeated testing and care by other providers. A new study published last month (June, 2019) in the journal PlosOne , shows that all this can be improved when these complex patients have access to a patient portal . “A patient portal is a secure online website that gives patients convenient, 24-hour access to personal health information from anywhere with an Inte...
Post a Comment
Read more